FDA IND

Mabwell Advances SST001 PET Tracer to Phase I Trial

SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...

By cGxPwire Editor
April 15, 2026

Bio-Pharma

Enveric Biosciences Gains U.S. Patent for EVM301

CAMBRIDGE, Mass., March 31, 2026 Enveric Biosciences has strengthened its position in the rapidly evolving neuropsychiatric drug development space...

By cGxPwire Editor
April 1, 2026

Bio-Pharma

Gyre Therapeutics Advances Fibrosis-First Pipeline with Strong Q3 Growth and Regulatory Momentum

Dateline — San Diego, California, November 7, 2025:Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 2025 financial results and a...

By cGxPwire Editor
November 9, 2025

Bio-Pharma

Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation

Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...

By cGxPwire Editor
November 9, 2025

Bio-Pharma

Whitehawk Therapeutics Identifies PTK7 as a Broadly Expressed ADC Target Across Solid Tumors

MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...